FDA approves weekly diabetes drug that may also be beneficial for weight loss
The FDA has approved semaglutide injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The FDA has approved semaglutide injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Type 2 diabetes risk is increased in young adults through antidepressant use, specifically the duration of use and the cumulative dose.
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
After the inclusion of recent negative studies, a statistically significant association between AD use and diabetes was observed.
The statement includes advances in care since the ADA’s last position statement was published in 2003.
Lifestyle interventions maintain glycemic control in patients with type 2 diabetes.
Consumption of alcohol 3 to 4 days weekly is associated with a significantly lower risk for diabetes in men and women.
Adulthood weight gain is associated with an increased risk of major chronic diseases and mortality.
HIV-infected patients on ART had approximately 4 and 1.5 greater odds of developing diabetes mellitus and metabolic syndrome, respectively.
Degludec is noninferior to glargine regarding the incidence of major cardiovascular events among patients with type 2 diabetes.